# Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

> **NCT07121829** · PHASE1 · TERMINATED · sponsor: **Day One Biopharmaceuticals, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Melanoma
- Solid Tumor
- Pilocytic Astrocytoma
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- MAP Kinase Family Gene Mutation
- RAS Mutation
- RAF Mutation
- MEK Mutation

## Interventions

- **DRUG:** Tovorafenib
- **DRUG:** Tovorafenib Drug: Pimasertib

## Key facts

- **NCT ID:** NCT07121829
- **Lead sponsor:** Day One Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-02
- **Primary completion:** 2024-12-18
- **Final completion:** 2024-12-18
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121829, "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07121829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*